Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion Allograft
01. Oktober 2024 08:37 ET
|
Merakris Therapeutics
Merakris to showcase Lyophilized Amnion Chorion, Dermacyte AC Matrix, at the Fall Symposium for Advanced Wound Care (SAWC) in Las Vegas on October 2-5.
Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
05. September 2024 06:30 ET
|
Merakris Therapeutics
Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.
Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations
09. Mai 2024 06:30 ET
|
Merakris Therapeutics
Merakris Therapeutics announced today that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.
Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care
12. März 2024 06:30 ET
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- A recent multicenter study has demonstrated encouraging effectiveness and safety of Merakris Therapeutics’ Dermacyte® Amniotic Wound...
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
20. Februar 2024 06:15 ET
|
Merakris Therapeutics
Merakris to present encouraging Phase 2 clinical drug trial data at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25.
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
05. Dezember 2023 06:30 ET
|
Merakris Therapeutics
Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.
Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program
12. Oktober 2023 06:30 ET
|
Merakris Therapeutics
The Opticyte Tears program uses patients’ blood serum to create Autologous Serum Tears from the convenience of their homes.
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team
15. August 2023 06:30 ET
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...
Merakris Announces Review in Biomedicines Medical Journal Highlighting Therapeutic Potential of Cell-Free Amniotic Fluid
29. November 2022 06:15 ET
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid...
Merakris Sponsored Study Opens Door to Precision-Based Approaches to Wound Healing
13. September 2022 06:00 ET
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- A recently published manuscript containing research sponsored, in part, by Merakris Therapeutics has opened the door to more...